Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
bluebird bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
bluebird bio Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
bluebird bio Raises US$60 Million In Series D Financing 12
Partnerships 14
bluebird bio and Gritstone Oncology Enter into Agreement 14
Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 15
Celgene and Bluebird Enter into Co-Development Agreement 16
Kite Pharma Enters into Co-Development Agreement with Bluebird bio 17
bluebird bio Amends Co-Development Agreement With Celgene 18
Licensing Agreements 19
bluebird bio Enters into Licensing Agreement with TC BioPharm 19
GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 20
Novartis Pharma Enters into Licensing Agreement with bluebird bio 21
MediGene Expands Licensing Agreement with bluebird bio 22
Bluebird bio Enters Into Licensing Agreement With ViroMed 23
bluebird bio Enters into Licensing Agreement with National Institutes of Health 24
bluebird bio Enters into Licensing Agreement with Biogen 25
Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 26
Equity Offering 27
bluebird bio Raises USD632.5 Million in Public Offering of Shares 27
bluebird bio Raises USD651.3 Million in Public Offering of Shares 29
bluebird bio Raises USD460 Million in Public Offering of Shares 31
bluebird bio Raises USD250 Million in Public Offering of Shares 33
Bluebird bio Raises USD500 Million in Public Offering of Shares 35
Bluebird bio Raises USD259 Million in Public Offering of Shares 37
Bluebird bio Raises USD117.3 Million in Public Offering of Shares 39
bluebird bio Completes IPO For US$116 Million 41
Acquisition 43
Bluebird bio Acquires Precision Genome Engineering 43
bluebird bio Inc – Key Competitors 44
bluebird bio Inc – Key Employees 45
bluebird bio Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
Nov 01, 2018: bluebird bio reports third quarter 2018 financial results and highlights operational progress 47
Aug 02, 2018: bluebird bio reports second quarter 2018 financial results and highlights operational progress 50
May 02, 2018: bluebird bio Announces First Quarter 2018 Financial Results 53
Feb 21, 2018: bluebird bio Announces Fourth Quarter and Full Year 2017 Financial Results 54
Nov 01, 2017: bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress 56
Aug 02, 2017: bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress 58
May 03, 2017: bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress 60
Feb 22, 2017: bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress 61
Corporate Communications 63
Feb 14, 2018: bluebird bio Names Alison Finger As Chief Commercial Officer 63
Sep 20, 2017: bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors 64
Jun 08, 2017: bluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors 65
Product News 66
12/11/2017: bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent ß-Thalassemia at American Society of Hematology Annual Meeting 66
10/04/2017: bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine 68
10/04/2017: Gene therapy halts progression of childhood cerebral adrenoleukodystrophy in clinical trial 70
09/06/2017: bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy at Child Neurology Society 2017 Annual Meeting 72
06/26/2017: bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D Drug Product in Cerebral Adrenoleukodystrophy 73
06/23/2017: bluebird bio Presents New Data from HGB-205 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease at European Hematology Association Annual Meeting 74
06/15/2018: bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia at Annual Congress of the European Hematology Association 76
04/18/2018: bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia 78
03/01/2017: bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine 80
01/31/2018: Sickle cell gene therapy to boost fetal hemoglobin: A 70-year timeline of discovery 81
Clinical Trials 82
Jun 15, 2018: bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association 82
May 17, 2018: bluebird bio to Present New Data from LentiGlobin Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association 84
Dec 10, 2017: bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent ß-Thalassemia at American Society of Hematology Annual Meeting 86
Nov 16, 2017: bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin in Patients with Transfusion-Dependent ß-Thalassemia (TDT) and ß0/ß0 Genotype 88
Nov 01, 2017: bluebird bio to Present New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent ß-Thalassemia at ASH Annual Meeting 89
Sep 28, 2017: bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma 92
Jun 23, 2017: bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobin Drug Product at European Hematology Association (EHA) Annual Meeting 93
May 18, 2017: bluebird bio to Present New Data from LentiGlobin Clinical Studies at European Hematology Association Annual Meeting 94
Feb 03, 2017: bluebird bio Announces First Patient Treated with LentiGlobin Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease 95
Other Significant Developments 96
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 96
Appendix 97
Methodology 97
About GlobalData 97
Contact Us 97
Disclaimer 97
bluebird bio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
bluebird bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
bluebird bio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
bluebird bio Raises US$60 Million In Series D Financing 12
bluebird bio and Gritstone Oncology Enter into Agreement 14
Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 15
Celgene and Bluebird Enter into Co-Development Agreement 16
Kite Pharma Enters into Co-Development Agreement with Bluebird bio 17
bluebird bio Amends Co-Development Agreement With Celgene 18
bluebird bio Enters into Licensing Agreement with TC BioPharm 19
GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 20
Novartis Pharma Enters into Licensing Agreement with bluebird bio 21
MediGene Expands Licensing Agreement with bluebird bio 22
Bluebird bio Enters Into Licensing Agreement With ViroMed 23
bluebird bio Enters into Licensing Agreement with National Institutes of Health 24
bluebird bio Enters into Licensing Agreement with Biogen 25
Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 26
bluebird bio Raises USD632.5 Million in Public Offering of Shares 27
bluebird bio Raises USD651.3 Million in Public Offering of Shares 29
bluebird bio Raises USD460 Million in Public Offering of Shares 31
bluebird bio Raises USD250 Million in Public Offering of Shares 33
Bluebird bio Raises USD500 Million in Public Offering of Shares 35
Bluebird bio Raises USD259 Million in Public Offering of Shares 37
Bluebird bio Raises USD117.3 Million in Public Offering of Shares 39
bluebird bio Completes IPO For US$116 Million 41
Bluebird bio Acquires Precision Genome Engineering 43
bluebird bio Inc, Key Competitors 44
bluebird bio Inc, Key Employees 45
bluebird bio Inc, Other Locations 46
bluebird bio Inc, Subsidiaries 46
List of Figures
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9